Table 1. Comparison of CT use among ED visits and hospitalizations for patients with IBD with pharmaceutical coverage.
| No CT (n = 105,782) | CT (n = 38,365) | Test Statistic(DF) | Test Value | p value | |
|---|---|---|---|---|---|
| Age, mean (SD) | 43.7 (18.5) | 43.7 (16.1) | t(144145) | 0.09 | 0.92 |
| Female (%) | 61,171 (57.8) | 21,753 (56.7) | C2(1) | 14.64 | <0.001 |
| Diagnosis Crohn's Diagnosis (%) |
46,455 (43.9) | 17,360 (45.3) | C2(2) | 564.30 | <0.001 |
| Ulcerative Colitis (%) | 20,852 (19.7) | 5,525 (14.4) | |||
| Indeterminate Colitis (%) | 38,475 (36.4) | 15,480 (40.4) | |||
| Anti-TNF use at time of visit (%) | 5,599 (5.3) | 2,117 (5.5) | C2(1) | 2.82 | 0.09 |
| Narcotic use in previous 90 days (%) | 37,779 (35.7) | 13,612 (35.5) | C2(1) | 0.67 | 0.41 |
| Immunomodulator use (%) | 8,180 (7.7) | 2,833 (7.4) | C2(1) | 4.85 | 0.03 |
| Steroid use in prior 90 days (%) | 12,143 (11.5) | 4,428 (11.5) | C2(1) | 0.10 | 0.74 |
| Length of stay in days, mean (SD) | 4.8 (6.1) | 5.9 (6.9) | t(102968) | -25.16 | <0.001 |